Back to Academy

The Four Clinical Trial Phases (and the MedTech Equivalents)

Bringing a new medical product to market safely and compliantly requires systematic, evidence-based testing in humans. Most new medical products need clinical evidence before they can be approved, generated through a series of structured studies. The type and depth of that testing depends on the product and the level of risk it poses to patients.

Not every medical product needs a dedicated clinical trial. Low-risk devices, such as Class I devices (for example bandages, tongue depressors or non-powered wheelchairs), typically do not require a new clinical investigation. Manufacturers must still demonstrate safety and performance through a clinical evaluation, but this can usually draw on existing data, such as published literature and post-market experience with similar products.

In the pharmaceutical industry, clinical testing follows a phased path to evaluate safety, dosage and efficacy. The medical device industry (MedTech) uses a similar structure but moves away from the rigid Phase I to IV drug model. How a clinical investigation is structured depends on what is being tested: a chemical compound, an implantable device, a diagnostic assay or clinical software.

Below, we look at the four pharma phases first, then translate them stage by stage for MedTech, in vitro diagnostics (IVD) and digital health teams.

In short

  • How many phases of clinical trials are there? In pharmaceutical drug development, there are four main phases (I-IV). Each tests safety, dosage, efficacy and long-term outcomes in progressively larger patient populations. Medical devices and diagnostics follow a related but differently named pathway.
  • Clinical investigation phases for medical devices and digital health: Medical devices (MedTech), in vitro diagnostics (IVD) and software as a medical device (SaMD) do not use Phases I-IV. They follow structured clinical investigation stages that move from pilot or feasibility studies to pivotal trials, followed by post-market clinical follow-up (PMCF) and post-market surveillance (PMS).
  • Who is Ledidi? Ledidi is a Norwegian software company founded by academic surgeons and software engineers. We provide a unified, secure cloud platform, comprising Ledidi Core, Ledidi Trials and Ledidi Registries, that combines data capture, real-time analytics and global collaboration.

How many clinical trial phases are there?

There are four clinical trial phases. Each phase is a separate trial, or set of trials, and a drug must show acceptable results in one phase before it can progress to the next. Across all phases, the goal is to establish whether the product is safe and effective for human use.

Pharmaceutical clinical trials are tightly regulated in every major market:

  • EU: Trials are conducted under the Clinical Trials Regulation (CTR), Regulation (EU) No 536/2014, which has applied to all clinical trials in the EU since 31 January 2025.
  • US: The Food and Drug Administration (FDA) regulates trials through the Investigational New Drug (IND) application, set out in Title 21 of the Code of Federal Regulations (CFR), Part 312.
  • UK: The Medicines and Healthcare products Regulatory Agency (MHRA) authorises and oversees clinical trials.

Internationally, trials follow the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guideline, ICH E6 (R3).

Medical devices and diagnostics are governed separately:

  • EU: The Medical Device Regulation (MDR), Regulation (EU) 2017/745, and the In Vitro Diagnostic Regulation (IVDR), Regulation (EU) 2017/746.
  • US: The FDA Investigational Device Exemption (IDE) under 21 CFR Part 812.
  • International: The device equivalent of GCP is ISO 14155:2020.

Note: The terms "clinical trials", "clinical studies" and "clinical investigations" are often used interchangeably. "Clinical investigations" is the most common term in the medical device industry.

Read more about compliance in clinical trials in our guide to 21 CFR Part 11.

An overview of the four clinical trial phases

In pharmaceutical development, the four phases are the standard roadmap for approving new drugs. Phases I-IV apply only to drugs and biologics. Medical devices instead go through pilot, pivotal and post-market stages, which we cover later in this article.

PhaseRegulatory stagePrimary goalTypical cohort sizeTypical duration
Phase IPre-market (exploratory)Safety, tolerability, pharmacokinetics, safe dosage20-80 healthy volunteers or patientsSeveral months
Phase IIPre-market (exploratory)Preliminary efficacy, optimal dosing, common side effects100-300 target patientsSeveral months to 2 years
Phase IIIPre-market (confirmatory)Confirm therapeutic benefit, monitor adverse events, compare with standard of care1,000-3,000+ target patients1-4 years
Phase IVPost-market (surveillance)Real-world safety, long-term outcomes, rare adverse effectsThousands (general patient population)Ongoing

Phase I

In the first phase, researchers test a drug or treatment in people for the first time, often called a first-in-human study. Participants are usually healthy volunteers. In oncology and other high-risk areas, Phase I is run in patients with the condition instead. The objective is to establish a safe dose range and the maximum tolerated dose, identify side effects, and understand pharmacokinetics (how the body absorbs, distributes and clears the drug) and pharmacodynamics (how the drug affects the body).

  • Purpose: Exploratory.
  • Typical cohort size: 20 to 80 healthy volunteers or patients.
  • Typical duration: Several months.

Phase II

The drug or treatment is then given to a larger group of patients with the target condition to assess whether it works and to find the optimal dose. Phase II is often split into Phase IIa, which provides proof of concept, and Phase IIb, which focuses on dose-finding. These studies are often randomised and controlled. Identifying safety concerns remains a key priority.

  • Purpose: Exploratory.
  • Typical cohort size: 100 to 300 patients with the target disease or condition.
  • Typical duration: Several months and up to two years.

Phase III

Phase III moves from smaller groups to testing the drug or treatment in a large patient population. These trials are usually randomised, controlled, multicentre and often multinational. The objective is to confirm effectiveness, monitor side effects, compare the treatment with the current standard of care, and collect the information needed for safe use.

Phase III results form the basis of the marketing application. In the EU, this is a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA). In the US, it is a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA.

  • Purpose: Confirmatory.
  • Typical cohort size: 1,000 to 3,000 patients.
  • Typical duration: 1 to 4 years.

Phase IV

Phase IV studies take place after the drug has been approved and is commercially available. Researchers continue to track safety and effectiveness in routine clinical practice, where patient populations are broader and more varied than in earlier trials. Phase IV is also an opportunity to learn more about the benefits and best use cases of the treatment.

Regulators may require these studies as a condition of approval. In the EU, they include Post-Authorisation Safety Studies (PASS) and Post-Authorisation Efficacy Studies (PAES). In the US, they are known as postmarketing requirements and commitments. Routine pharmacovigilance, the ongoing monitoring of adverse event reports, runs alongside Phase IV studies.

  • Purpose: Post-market.
  • Typical cohort size: The general patient population after approval.
  • Typical duration: Ongoing after approval, including real-world surveillance.

Read more in our guide to Phase 4 clinical trials.

Clinical trial phases beyond pharma: MedTech, IVD and SaMD equivalents

Clinical trial phases are not the same for medical device investigations. If you are a MedTech or diagnostics team, you will not run a "Phase III" trial in the pharma sense. Higher-risk devices typically complete an equivalent pivotal or clinical validation stage, with comparable evidentiary weight.

Device studies differ from drug trials in several important ways:

  • Evidence scales with risk class: Requirements increase with the device's risk class (Class I, IIa, IIb and III in the EU; Class I to III with the FDA).
  • Design evolves during the study: Devices are often refined between, and even during, investigations.
  • Outcomes depend on the user: Results are affected by operator skill, the learning curve and clinical workflow, so usability, ergonomics and reducing human error matter. Unlike drug trials, which aim to establish a maximum tolerated dose, device studies focus on risk class and operational value.
  • Blinding is often impossible: It is rarely possible to blind surgeons to an implant or give patients a "placebo" device.
  • A different GCP standard: Investigations follow ISO 14155:2020 rather than ICH E6.

Clinical investigation phases in the medical device industry (MedTech)

Clinical stage 1: pilot (pre-market)

Before any human use, the device goes through preclinical testing, including bench testing and biocompatibility assessment under ISO 10993. Teams then run small pilot studies to evaluate initial safety and provide proof of concept. These typically include:

  • First-in-human (FIH) studies: The first use of the device in people.
  • Early feasibility studies (EFS): Small studies of an early design that may still change. The FDA runs a dedicated EFS programme to support these studies in the US.
  • Traditional feasibility studies: Studies of a near-final design, used to inform the design of the pivotal study.
  • Purpose: Exploratory.
  • Typical cohort size: 10 to 30 patients.
  • Typical duration: 12 to 18 months for the primary execution phase, with a total timeline of 3 to 5 years including long-term patient follow-up.

Clinical stage 2: pivotal (pre-market)

Still before the device is on the market, a larger volume of evidence is collected to draw statistically robust conclusions on its safety and effectiveness. This is a critical step for regulatory submission. In the EU, pivotal data feeds the manufacturer's Clinical Evaluation Report (CER), which is assessed by a notified body. For some Class III implantable and certain Class IIb devices, an expert panel also reviews the evidence through the Clinical Evaluation Consultation Procedure (CECP). In the US, pivotal data typically supports a Premarket Approval (PMA) or De Novo submission.

Not every device needs a pivotal study. Many devices cleared through the FDA 510(k) pathway rely on substantial equivalence to an existing predicate device, and lower-risk EU devices can often rely on existing clinical data.

  • Purpose: Confirmatory.
  • Typical cohort size: 100 to 500+ patients.
  • Typical duration: 3 to 5+ years.

Clinical stage 3: post-market clinical follow-up (PMCF)

Once a device is on the market, the manufacturer must keep collecting clinical data. Post-market surveillance (PMS) is the overall system for monitoring a marketed device. It covers complaints, vigilance reporting, trend analysis and the Periodic Safety Update Report (PSUR). PMCF is the clinical evidence part of PMS, set out in MDR Annex XIV Part B.

As with Phase IV in pharma, the objective is to track long-term performance, reliability and rare adverse events in real-world use. Under the MDR, PMCF must always be considered, and if a manufacturer decides it is not needed, that decision must be justified. Clinical registries are an accepted PMCF route, particularly for high-risk and orphan devices, where long-term data across many sites matters most.

  • Purpose: Post-market.
  • Typical cohort size: Patients across real-world cohorts and clinical registries.
  • Typical duration: Ongoing throughout the commercial lifetime of the device.

Read more: our guides to post-market clinical follow-up (PMCF) activities and to medical device post-market surveillance.

Clinical investigation phases for in vitro diagnostics (IVD)

Under the IVDR, clinical evidence for an in vitro diagnostic comes from a performance evaluation built on three pillars:

  • Scientific validity and analytical performance: Scientific validity establishes that the analyte (the substance the test measures) is genuinely associated with the clinical condition. Analytical performance shows that the test measures the analyte accurately and reliably, covering sensitivity, specificity, precision and limits of detection.
  • Clinical performance: Clinical performance shows that the test produces results that correlate with the clinical condition in the intended population. This is usually demonstrated through clinical performance studies. Many of these studies use leftover or banked samples rather than enrolling patients prospectively, which changes the data capture and consent requirements. Interventional studies, where test results influence patient management, need regulatory authorisation before they start.
  • Post-market performance follow-up (PMPF): After CE marking, manufacturers run PMPF, the IVD equivalent of PMCF, set out in IVDR Annex XIII Part B. PMPF confirms that the test continues to perform as intended across real-world sites, populations and sample types.

Clinical investigation phases for software as a medical device (SaMD)

SaMD follows the same three-part logic. It is set out internationally by the International Medical Device Regulators Forum (IMDRF) and, in the EU, by the Medical Device Coordination Group guidance MDCG 2020-1.

  • Valid clinical association and analytical validation: Valid clinical association shows that the software's output is linked to the targeted clinical condition. Analytical, or technical, validation shows that the software processes input data correctly, accurately and reproducibly.
  • Clinical validation: Clinical validation shows that the software's output achieves its intended purpose in the target population. This is often done through retrospective studies on existing datasets, or reader studies comparing clinicians' decisions with and without the software.
  • PMCF/PMPF and drift monitoring (AI): After launch, PMCF applies, or PMPF if the software is an IVD. For software that uses artificial intelligence (AI), performance can drift over time as patient populations, clinical practice or input data change. Drift and bias must therefore be monitored continuously, and this needs to be designed into the evidence plan from the start. In the US, the FDA's Predetermined Change Control Plan (PCCP) guidance allows manufacturers to agree planned model updates in advance. In the EU, the AI Act adds further obligations for high-risk AI in medical devices, with timelines currently being revised under a provisionally agreed amendment.

Digital security and compliance in Ledidi Trials

Ledidi Trials is a dedicated module for clinical trials regulated under Good Practice (GxP) quality guidelines. It is built for regulatory clinical trials run by MedTech companies, biotech companies and Contract Research Organisations (CROs). Whichever pathway your studies follow (Phase I-IV, or pilot, pivotal and PMCF), Ledidi Trials supports GxP-regulated data capture across all stages.

Ledidi Trials was independently audited and confirmed audit-ready in January 2026 by Thomas Pauly CISA / DHC, verifying compliance with key regulatory expectations, including FDA 21 CFR Part 11, ICH GCP E6 (R3) and ISPE GAMP 5.

Explore Ledidi Trials

Watch: How to set up a clinical trial in Ledidi Trials

In this short video, see how a study team builds a study in Ledidi Trials, from creating the electronic Case Report Form (eCRF) to going live with sites.

Watch more videos of Ledidi in practice

How Ledidi can benefit your clinical trial design

Medical device and diagnostic manufacturers face an evolving regulatory landscape under the EU MDR, IVDR and FDA requirements. Generating the necessary clinical evidence often involves several study types over a product's lifecycle, from small early feasibility studies and IVD performance studies, to multicentre pivotal trials, to long-term PMCF, PMPF and registries.

Managing these across disconnected tools leads to data silos, costly data migrations and repeated vendor contracting. Ledidi removes that friction by bringing EDC, clinical data management and registries together in one audit-ready cloud platform:

  • A smooth path from pilot to pivotal to PMCF: Move from an early feasibility study into a pivotal investigation or a long-term registry on the same platform, without retraining clinical site teams.
  • No-code eCRF configuration: Build and amend electronic Case Report Forms (eCRFs) quickly to match complex device and surgical workflows, without relying on external programmers. One MedTech sponsor went from first interaction to a fully contracted and set-up study in 16 days, with their own team building the eCRF in-house.
  • Inspection-ready GxP compliance: Keep full audit trails, 21 CFR Part 11 electronic signatures and ICH GCP E6 (R3) compliance across every study stage.

Because Ledidi Core, Trials and Registries share the same secure platform, customers can run every stage of their clinical evidence programme in one place, from early feasibility and pivotal studies to Phase I-IV trials, PMCF and long-term registries. Study teams and clinical sites keep the same login, the same interface and the same training throughout.

Whether you are moving from pilot to pivotal, or from Phase II to Phase III, that means faster study start-up, direct ownership of your trial data and a platform built to stay inspection-ready across the whole evidence lifecycle.

Read more about clinical trials from Ledidi Academy

Frequently asked questions

What is the difference between clinical trial phases and MedTech development stages?

Pharmaceutical phases (I-IV) evaluate how human biological systems interact with chemical or biological compounds across a range of standard doses. MedTech studies instead evaluate physical human-machine interactions, ergonomics, device longevity and procedural success. Because the risk profiles and mechanisms are so different, MedTech uses stage names such as feasibility or pilot, pivotal and post-market clinical follow-up (PMCF) rather than numbered phases.

How long does each clinical trial phase take?

In pharmaceutical development:

  • Phase I: Several months.
  • Phase II: Several months to 2 years.
  • Phase III: 1 to 4 years.
  • Phase IV: Several years, and ongoing for as long as the drug is on the market.

Total drug development, from preclinical research to approval, is commonly estimated at 10 to 15 years. In MedTech, timelines vary widely by device class and follow-up requirements (see the stage durations above), and PMCF continues for as long as the device is marketed.

What happens after Phase IV?

Phase IV continues for as long as the drug remains commercially available. If the data reveals new risks, regulators may require changes to the product's labelling, restrictions on its use or, in serious cases, withdrawal from the market. Post-market findings can also prompt new Phase II or Phase III trials to explore new indications.

For medical devices, the equivalent is PMCF, which also continues for the device's commercial lifetime. If the data reveals new risks, a regulatory revision may be required, and post-market findings can likewise prompt new pivotal studies.

Sources

More From Ledidi Academy